Perhaps the   drug developed from a cooperative research and development agreement   —   the cancer drug Taxol   —   was the subject of several congressional hearings in the early 1990s that investigated whether the drug’s maker,   Squibb, charged too much and whether the government recouped enough of its investment. In the end, the pricing was left unchanged. 